SEC 1344 (11091)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC File Number 000-21615
CUSIP Number __________
(Check One): [X] Form 10-K and Form 10-KSB [ ] Form 20-F [ ] Form
11-K [ ] Form 10-Q and Form 10-QSB
[ ] Form N-SAR
For Period Ended: December 31, 1998 [ ] Transition Report on Form
10-K [ ] Transition Report on Form 20-F [ ] Transition Report on
Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report
on Form N-SAR For the Transition Period Ended:
- ------------------------------------------------------------------------------
Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
- ------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- ------------------------------------------------------------------------------
- ------------------------------------------------------------------------------
- ------------------------------------------------------------------------------
Part I - Registrant Information
- ------------------------------------------------------------------------------
Full Name of Registrant Boston Biomedica, Inc.
Former Name if Applicable
- ------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
375 West Street
- ------------------------------------------------------------------------------
City, State and Zip Code
West Bridgewater, MA 02379 - 1040
- ------------------------------------------------------------------------------
Part II - Rules 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
|X| (a) The reasons described in reasonable detail in Part III
of this form could not be eliminated without
unreasonable effort or expense;
|X| (b) The subject annual report, semi-annual report,
transition report on Form 10-K, Form 20-F, 11-K, Form
N-SAR, or portion thereof, will be filed on or before
the fifteenth calendar day following the prescribed due
date; or the subject quarterly report or transition
report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the
prescribed due date; and
|_| (c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
- ------------------------------------------------------------------------------
Part III - Narrative
- ------------------------------------------------------------------------------
State below in reasonable detail the reasons why Form 10-K, Form 10-KSB, 11-K,
20-F, 10-Q, Form 10-QSB, N-SAR, or the transition report or portion thereof,
could not be filed within the prescribed time period. (attach extra sheets if
needed)
The registrant has been implementing an enterprise resource planning software
system. This has required a substantial amount of management time from key
people involved in the annual report process. As a result, the registrant was
unable, without unreasonable effort and expense, to complete and file its Annual
Report on Form 10-K by March 31, 1999.
- ------------------------------------------------------------------------------
Part IV - Other Information
- ------------------------------------------------------------------------------
(1) Name and telephone number of person to contact in regard to this
notification
Steven R. London 617
856-8313
(Name) (Area Code)
(Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed? If the
answer is no, identify report(s). Yes [X] No [ ]
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or portion
thereof?
Yes [X]
No [ ]
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
The registrant announced in a press release dated February 25, 1999 that revenue
for the year ended December 31, 1998 increased to $26,081,076, an increase of
$3,781,739 or 17% compared with revenue of $22,299,337 for the fiscal year ended
December 31, 1997. The Company had a net loss for 1998 of $(4,388,719), or
$(0.94) per diluted share, compared with net income of $1,004,834 or $0.21 per
diluted share in 1997. Results for 1998 were adversely impacted by a number of
factors, the largest of which was the registrant's acquisitions of technology
and the remaining outstanding capital stock of BioSeq, Inc., which resulted in
charges for acquired in-process research and development for the year in the
amount of $4,200,000 ($3,900,000 after taxes).
The registrant expects to report these same results in its Annual Report on Form
10-K for the year ended December 31, 1998.
Boston Biomedica, Inc.
- ------------------------------------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: April 1, 1999 By /s/ Kevin W. Quinlan
----------------------------------
Name: Kevin W. Quinlan
Title: Senior Vice President,
Finance
#802735 v1 - LONDONSR - H7#701!.DOC - 11563/1
